Brief: Can-Fite Receives U.S. FDA Approval For Piclidenoson Psoriasis Registration Plan
29/06/2023 12:07
June 29 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE RECEIVES U.S. FDA’S GO AHEAD FOR PICLIDENOSON
PSORIASIS
REGISTRATION PLAN
Source text for Eikon: ID:nBw9wW54wa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage